The frequency of differentiated CD3(+)CD27(-)CD28(-) T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma

BACKGROUND: Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. Despite this heterogeneous response, blood pre-infusion biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales: Worel, Nina, Grabmeier-Pfistershammer, Katharina, Kratzer, Bernhard, Schlager, Martina, Tanzmann, Andreas, Rottal, Arno, Körmöczi, Ulrike, Porpaczy, Edit, Staber, Philipp B., Skrabs, Cathrin, Herkner, Harald, Gudipati, Venugopal, Huppa, Johannes B., Salzer, Benjamin, Lehner, Manfred, Saxenhuber, Nora, Friedberg, Eleonora, Wohlfarth, Philipp, Hopfinger, Georg, Rabitsch, Werner, Simonitsch-Klupp, Ingrid, Jäger, Ulrich, Pickl, Winfried F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868136/
https://www.ncbi.nlm.nih.gov/pubmed/36700229
http://dx.doi.org/10.3389/fimmu.2022.1004703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868136/
https://www.ncbi.nlm.nih.gov/pubmed/36700229
http://dx.doi.org/10.3389/fimmu.2022.1004703

Ejemplares similares